Dr Ashleys to acquire Impact BioMedical in strategic merger transaction.

Dr. Ashleys Limited, a Hong Kong-based pharmaceutical company, and Impact BioMedical Inc., a Texas-based biopharmaceuticals developer, have executed a merger and share exchange agreement to accelerate market reach for innovative pharmaceutical patents. Upon closing, Dr. Ashleys will acquire Impact BioMedical through a reverse merger, resulting in a newly formed combined entity traded on the NYSE American under the name "Dr Ashleys Limited." The transaction underscores the importance of innovation and collaboration in the biomedical industry.

Dr. Ashleys Limited, a Hong Kong-based global pharmaceutical company, and Impact BioMedical Inc., a Texas-based biopharmaceuticals developer, have executed a merger and share exchange agreement to accelerate market reach for innovative pharmaceutical patents. Upon closing, Dr. Ashleys will acquire Impact BioMedical through a reverse merger, resulting in a newly formed combined entity traded on the NYSE American under the name "Dr Ashleys Limited." The transaction underscores the importance of innovation and collaboration in the biomedical industry.

The merger, announced on June 23, 2025, represents a significant milestone for both companies. Dr. Ashleys, under the leadership of Dr. Kanans Visvanats, aims to integrate Impact Biomedical's impressive IP portfolio into its R&D efforts to develop groundbreaking therapies and expand its global health impact. Frank D. Heuszel, CEO of Impact Biomedical Inc., expressed enthusiasm about the partnership, noting that Dr. Ashleys' global reach and financial strength will provide the necessary resources and infrastructure to bring Impact Biomedical's innovations to market.

Key transaction terms include a merger subsidiary incorporated in Nevada, which will merge with and into Impact BioMedical, with Impact BioMedical being the surviving entity. Simultaneously, PubCo will acquire all issued and outstanding shares of Dr. Ashleys Bio Labs Limited, a Cayman Islands exempted company holding all shares of Dr. Ashleys. Upon closing, both Impact BioMedical and Dr. Ashleys will become wholly-owned subsidiaries of PubCo, operated by the management team of Dr. Ashleys with a new Board of Directors to be assembled.

The Boards of Directors of both Dr. Ashleys and Impact BioMedical have unanimously approved the proposed transaction, subject to shareholder approval and satisfaction of regulatory conditions, including SEC approval. Advisors BMI Capital LLC, Robinson & Cole LLP, Harney Westwood & Riegels, Sichenzia Ross Ference Carmel LLP, Revere Securities LLC, and Capital Formation Marketing, LLC, are serving as advisors to the transaction.

Dr. Ashleys Limited specializes in the development and manufacturing of APIs and orphan drugs for rare diseases, while Impact BioMedical Inc. focuses on innovative health and wellness solutions with a robust patent portfolio. Together, the combined entity aims to address critical health challenges through cutting-edge research and development.

For more information, interested parties are encouraged to review the Registration Statement on Form F-4 or S-4, which will be filed with the SEC and available on the SEC's website at www.sec.gov.

References:
[1] https://sg.finance.yahoo.com/news/dr-ashleys-limited-impact-biomedical-115200395.html
[2] https://www.tradingview.com/news/reuters.com,2025-06-23:newsml_GNX7grctX:0-dr-ashleys-limited-and-impact-biomedical-inc-announce-strategic-merger/